Accepting PhD Students

PhD projects

PhD and MPhil projects are available. Current research interests include: -Neuropathophysiology of Duchenne muscular dystrophy -RNA processing of the dystrophin gene -Therapeutic targeting of dystrophin in the brain -Role of the DMD gene in cancer -RNA processing in neurodegeneration -RNA-based gene therapy/therapeutics Please get in touch by e-mail or telephone.

Willing to speak to media

20072019

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Karen studied biochemistry at the University of Leeds spending one year as a sandwich student at GlaxoSmithKline (GSK), Essex.  At GSK Karen experienced the drug discovery process through performing large-scale purifications of protein drug targets.  Developing a strong interest in neurodegeneration Karen joined the lab of Dr Jean-Marc Gallo at the Institute of Psychiatry, King’s College London.  Her PhD “tau RNA processing in neurodegeneration: trans-acting factors regulating alternative splicing and mRNA localisation” was awarded in 2009.  As a post-doc in Dr Gallo’s lab Karen established proof-of-concept for RNA reprogramming strategies including RNA trans-splicing therapies for spinocerebellar ataxia type 1 and the tauopathies.  In 2010 Karen successfully translated her RNA expertise to the neuromuscular field and moved to the Dubowitz Neuromuscular Centre, Institute of Child Health, University College London (UCL).  Working with Professor Francesco Muntoni, Karen played a key role in developing antisense oligonucleotide-mediated exon skipping as a therapeutic strategy for Duchenne muscular dystrophy (DMD).  Her pre-clinical and clinical work in this area culminated in the first FDA-approved drug for DMD.  In 2015 Karen attained a lectureship at the University of Northampton where she founded and leads the Molecular Biosciences Research Group.  Her laboratory investigates the molecular mechanisms of neurological disorders with a focus on the neuropathophysiology of DMD.  Karen also consults for international pharmaceutical and biotechnology companies on methodology for clinical trial biochemical outcome measures and the development of exon skipping therapies.

Research Interests

Karen’s research is focused on RNA processing and the molecular mechanisms of neurodegeneration and neuromuscular disorders.  Current research projects and interests include:

-Neuropathophysiology of Duchenne muscular dystrophy

-The role of the DMD gene in cancer

-RNA processing of the dystrophin gene

-Therapeutic targeting of dystrophin in the brain

-RNA processing in neurodegeneration

-RNA-based gene therapy/therapeutics

Supervision

Amanda Ash; Sports, Exercise and Life Science

Cell migration in the neuropathophysiology of Duchenne muscular dystrophy

Michael Naidoo; Sports, Exercise and Life Science

The role of dystrophin in neurological malignancies.

Leanne Jones; Life Sciences

The role of dystrophin in head and neck cancers

Bill Robertson-Smith, Health and Society

Recurrence of synovial sarcoma: risk factors for relapse in a U.K. population.

Nermin Albalbeisi; Sports, Exercise and Life Science

Potential role of PAD2 in Ovarian Cancer.

 

Teaching Interests

Undergraduate teaching:

Karen teaches across the BSc (Hons) in Human Bioscience, Biomedical Science Biology programmes:

Module Leader:

  • SLS1017: Science Communication
  • SLS3010: Molecular and Cellular Neuroscience
  • SLS4005: Human Bioscience Dissertation

Teaching on other modules:

  • SLS2001: Genes and Genomics
  • SLS2010: Health and Disease 2
  • SLS2013: Bioscience Research Methods
  • SLS3002: Integrated Medical Genetics

Postgraduate teaching (taught programmes) 

  • MSc in Molecular Bioscience 

Education/Academic qualification

Master, University of Northampton

20162017

PhD, King's College London

20052009

Bachelor, University of Leeds

20012005

GlaxoSmithKline

20032004

Keywords

  • RM Therapeutics. Pharmacology
  • RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
  • RC0254 Neoplasms. Tumors. Oncology (including Cancer)
  • QP Physiology
  • QM Human anatomy
  • QH301 Biology
  • QH426 Genetics

Fingerprint Dive into the research topics where Karen Anthony is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles

Projects

Research Output

Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy

Naidoo, M. & Anthony, K., 13 Dec 2019, In : Molecular Neurobiology. p. 1-20 21 p.

Research output: Contribution to JournalArticle

Open Access
  • A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures

    Hiller, M., Falzarano, M. S., Garcia-Jimenez, I., Sardone, V., Verheul, R. C., Popplewell, L., Anthony, K., Ruiz-Del-Yerro, E., Osman, H., Goeman, J. J., Mamchaoui, K., Dickson, G., Ferlini, A., Muntoni, F., Aartsma-Rus, A., Arechavala-Gomeza, V., Datson, N. A. & Spitali, P., 2 Oct 2018, In : PLoS ONE. 13, 10, p. 1-15 15 p.

    Research output: Contribution to JournalArticle

    Open Access
    File
  • Open Access
    File
  • A UV cross-linking method combined with infrared imaging to analyse RNA–protein interactions

    Malmqvist, T., Spickett, C., Gallo, J-M. & Anthony, K., 5 Jun 2017, In : Biology Methods & Protocols. 2, 1, p. 1-4 4 p., 1.

    Research output: Contribution to JournalArticle

    Open Access
    File
  • Open Access
    File
  • Health and wellbeing amongst older people research in Northamptonshire

    Poole, H., Sixsmith, J., Parkes, J., Ward, A., Pyer, M., Campbell, J., Machado, L., Rehling, T., Youell, J., Carter, J., Oyebode, J., O’Malley, M., Anthony, K., Rogers, S., Jones, J., Siddons, L., Smith, L-A., Kay, A. D., Fraser, M., Score, J. & 8 others, El Khoury, L., Hameed, A., Albalbeisi, N., Durrant, L. G., Al-Zubaidi, R., Al-Rayahi, I., da Silva, K. & Taylor, J., 1 Aug 2017, (East Midlands Research into Ageing Network (EMRAN) Discussion Paper Series).

    Research output: Working PaperDiscussion Paper

    Open Access
    File
  • G.P.147 - Outcome measures for Duchenne muscular dystrophy from ambulant to non-ambulant: implications for clinical trials

    Ricotti, V., Eagle, M., Butler, J., Decostre, V., Deborah, R., Moraux, A., Anthony, K., Sleby, V., Guglieri, M., Van der Holst, M., Jansen, M., Morgan, J., de Groot, I., Niks, E., Verschuuren, J., Servais, L., Hogrel, J. Y., Voit, T., Straub, V. & Muntoni, F., 1 Oct 2015, In : Neuromuscular Disorders. 25, Supp 2

    Research output: Contribution to JournalAbstract

    Open Access
    File
  • G.P.228 - Micro RNA profile associated with the dystrophin level in Becker muscular dystrophy

    Zaharieva, I., Cirak, S., Anthony, K., Feng, L., Tasca, G., Ferlini, A., Morgan, J. & Muntoni, F., 1 Oct 2015, In : Neuromuscular Disorders. 25, Supp 2

    Research output: Contribution to JournalAbstract

    Open Access
    File
  • Prizes

    Poster prize

    Anthony, Karen (Recipient), 2012

    Prize

  • Activities

    Understanding the brain in Duchenne muscular dystrophy

    Karen Anthony (Author)

    8 Jun 2020

    Activity: Academic Talks or PresentationsOral presentationResearch

    PhD by publication internal examiner

    Karen Anthony (Examiner)

    2019

    Activity: ExaminationsExaminationResearch

    PhD internal examiner

    Karen Anthony (Examiner)

    2019

    Activity: ExaminationsExaminationResearch

    PhD external examiner

    Karen Anthony (Examiner)

    2019

    Activity: ExaminationsExaminationResearch

    COST Action: CA17103. Delivery of Antisense RNA Therapeutics

    Karen Anthony (Participant)

    25 Feb 201927 Feb 2019

    Activity: Participating in or organising a conference or workshopParticipating in a conference or workshopResearch

    File

    University of Northampton (Organisational unit)

    Karen Anthony (Chair)

    2018 → …

    Activity: Membership of a Board, Committee, Council or NetworkMembership of boardResearch

    11th annual neuromuscular translational research conference

    Karen Anthony (Participant)

    Apr 2018

    Activity: Participating in or organising a conference or workshopParticipating in a conference or workshopResearch

    Final COST Action meeting

    Karen Anthony (Participant)

    22 Mar 2017

    Activity: Participating in or organising a conference or workshopParticipating in a conference or workshopResearch

    Impacts

    FDA approves first drug to treat Duchenne muscular dystrophy (DMD)

    Karen Anthony (Co-Investigator)

    Impact: Public policy impacts, Health and Well-Being impacts, Quality of life impacts, 03: Good Health and Well-Being (UN SDG)